Ruben Van Dijck

Rotterdam, ZH, Netherlands

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 12 publications

NFкB pathway suppression as a key driver of pacritinib response in high-risk myelofibrosis.

NFкB pathway suppression as a key driver of pacritinib response in high-risk myelofibrosis.

Journal: British journal of haematology

Published: May 12, 2026

Correction: Pacritinib in transplant-eligible myelofibrosis: final analysis of the phase II HOVON-134 trial.

Correction: Pacritinib in transplant-eligible myelofibrosis: final analysis of the phase II HOVON-134 trial.

Journal: Bone marrow transplantation

Published: May 05, 2026

A critical view of the BJH publication on the lack of benefit of second-line daratumumab in patients with functional high-risk multiple myeloma.

A critical view of the BJH publication on the lack of benefit of second-line daratumumab in patients with functional high-risk multiple myeloma.

Journal: British journal of haematology

Published: March 02, 2026

Pacritinib in transplant-eligible myelofibrosis: final analysis of the phase II HOVON-134 trial.

Pacritinib in transplant-eligible myelofibrosis: final analysis of the phase II HOVON-134 trial.

Journal: Bone marrow transplantation

Published: October 20, 2025

Pacritinib in transplant-eligible myelofibrosis: final analysis of the phase II HOVON-134 trial.

Pacritinib in transplant-eligible myelofibrosis: final analysis of the phase II HOVON-134 trial.

Journal: Bone marrow transplantation

Published: October 20, 2025

Moving forward from spleen response as an endpoint in randomized controlled trials in myelofibrosis.

Moving forward from spleen response as an endpoint in randomized controlled trials in myelofibrosis.

Journal: Haematologica

Published: July 15, 2025

Clinical Benefit of Early Daratumumab Use in Multiple Myeloma is Undefined.

Clinical Benefit of Early Daratumumab Use in Multiple Myeloma is Undefined.

Journal: American journal of hematology

Published: April 07, 2025

Fedratinib for patients with myelofibrosis.

Fedratinib for patients with myelofibrosis.

Journal: The Lancet. Haematology

Published: October 26, 2024

Use of machine learning techniques to predict poor survival after hematopoietic cell transplantation for myelofibrosis.

Use of machine learning techniques to predict poor survival after hematopoietic cell transplantation for myelofibrosis.

Journal: Blood

Published: October 15, 2024

Luspatercept as Potential Treatment for Congenital Sideroblastic Anemia.

Luspatercept as Potential Treatment for Congenital Sideroblastic Anemia.

Journal: The New England journal of medicine

Published: April 12, 2023

The Role of Rituximab in the Treatment of Primary Central Nervous System Lymphoma.

The Role of Rituximab in the Treatment of Primary Central Nervous System Lymphoma.

Journal: Cancers

Published: March 24, 2021

Blinatumomab in relapsed/refractory diffuse large B cell lymphoma.

Blinatumomab in relapsed/refractory diffuse large B cell lymphoma.

Journal: Annals of hematology

Published: May 21, 2017

Showing 1-12 of 12

Last Updated: 09/26/2026